Drug Trial Radar · NCT03390010
Misoprostol Versus Active Management of Labour in CS
Last checked: Nov 20, 2026Latest source record: Nov 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Dec 28, 2017
Primary completion
Feb 28, 2018
Study completion Mar 6, 2018
Sponsor
- Lead sponsor
- Aljazeera HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cairo University
- First posted
- Jan 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 42 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Several treatment strategies are emplemented to prevent post delivery hemorage and decreasing maternal morbidity and mortality .
Conditions
- Cesarean Section
Interventions
Misoprostol + syntocinon and using extra uterotonic drugs when needed ; methergineDrug
medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Syntocinon and using extra uterotonic drugs when needed ; methergine carboprostDrug
medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and using extra uterotonic drugs when needed ; methergine, carboprost
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of participants who passed cesarean section without postpartum hemorageTime frame: within 2 days post CS
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Algazeerah
Giza, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.